Apogee Therapeutics, Inc.

NASDAQ:APGE

Biotechnology

Healthcare
$135.07 +1.18%

+$1.05 today

Market cap
$8.36B
Beta
0.62
P/E (TTM)
-22.7
EPS (TTM)
-$3.94
52W Low $34.34High $95.32

Volume 0.00M

Average 0.97M

APGE EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Apogee Therapeutics, Inc.NASDAQ: APGE

EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026

EPS (Basic) remains negative

Q2 FY2026 EPS (Basic) was -$1.14, compared with -$1.13 a year earlier. Trailing-twelve-month EPS (Basic) was -$4.34.

Context

  • EPS (Basic) grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 10 analysts of -$4.44 (-5.3%) for the fiscal year ending Dec 2026, a step up from the -27.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1.14-7.5% QoQ
Last fiscal yearDec 2025
-$4.22-27.9% YoY
LTMJun 2026
-$4.34-4.3% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.9%-0.9%+0.0 pp
1 year-27.9%-5.3%+22.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(4.22) USD
Year-over-year change
-27.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How APGE compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -4.3% is the 5th highest of 10, against a peer median of -18.9%.
APGE Competitors
EPS (Basic) for APGE and competitors
Company Period LTM YoY 3-year CAGR
LEGNLegend Biotech CorporationLTM Sep 2026-$0.01 USD+99.2%—
CNTACentessa Pharmaceuticals plcLTM Mar 2026-$1.78 USD+1.7%—
ZLABZai Lab LimitedLTM Jun 2026-$1.79 USD+69.8%—
CGONCG Oncology, Inc. Common stockLTM Sep 2026-$2.77 USD-35.1%—
CELCCelcuity Inc.LTM Jun 2026-$4.29 USD-24.3%—
APGEApogee Therapeutics, Inc.LTM Jun 2026-$4.34 USD-4.3%—
XENEXenon Pharmaceuticals Inc.LTM Sep 2026-$4.7 USD-20.8%—
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$6.11 USD-3.9%—
IRONDisc Medicine, Inc.LTM Sep 2026-$6.36 USD-18.9%—
AAPGAscentage Pharma Group InternationalFY2025-CN¥13.56 CNY-153.0%—
Peer median (excluding APGE) —-18.9%—

Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0001.42M
Gross Profit000(1.42M)
Gross Margin————
Research & Development27.79M68.42M167.87M214.71M
Selling, General & Admin2.94M24.58M49.01M70.88M
Operating Expenses30.73M93M216.87M284.18M
Depreciation & Amortization09.02M189K1.42M
EBITDA(39.79M)(74.97M)(181.94M)(254.15M)
EBITDA Margin————
Operating Income(30.73M)(93M)(216.87M)(285.6M)
Operating Margin————
Interest Income92K9.02M34.74M30.03M
Interest Expense9.15M000
Other Income / Expenses(9.06M)9.02M34.74M30.03M
Income Before Tax(39.79M)(83.99M)(182.13M)(255.57M)
Pre-Tax Margin————
Income Tax Expense0018K278K
Net Income(39.79M)(83.99M)(182.15M)(255.84M)
Net Margin————
EPS (Basic)(0.79)(1.66)(3.30)(4.22)
EPS (Diluted)(0.79)(1.66)(3.30)(4.22)
Weighted Avg Shares50.67M50.66M55.19M60.69M
Weighted Avg Shares (Diluted)50.67M50.66M55.19M60.69M

Apogee Therapeutics, Inc.

NASDAQ:APGE

Intrinsic Alpha fair value

Locked

Current Price

$135.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.